Last reviewed · How we verify
Dexycu intracameral dexamethasone
Dexycu is an intracameral corticosteroid that reduces inflammation in the anterior chamber of the eye following cataract surgery.
Dexycu is an intracameral corticosteroid that reduces inflammation in the anterior chamber of the eye following cataract surgery. Used for Postoperative inflammation and pain following cataract surgery.
At a glance
| Generic name | Dexycu intracameral dexamethasone |
|---|---|
| Also known as | Moxifloxacin 0.5%, Prolensa |
| Sponsor | Research Insight LLC |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Dexamethasone is a potent glucocorticoid that suppresses inflammatory cytokines and immune cell infiltration. When delivered directly into the eye via intracameral injection at the time of cataract surgery, it provides sustained local anti-inflammatory effects to reduce postoperative inflammation, pain, and corneal edema without systemic exposure.
Approved indications
- Postoperative inflammation and pain following cataract surgery
Common side effects
- Increased intraocular pressure
- Corneal edema
- Anterior chamber inflammation
- Eye discomfort
Key clinical trials
- Intravitreal and Intracameral DEX in NPDR (PHASE3)
- "A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu™) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation" (PHASE4)
- Effect of Intraoperative Dexamethasone on Post-op Dry Eye (PHASE4)
- A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery (PHASE4)
- A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1% (PHASE4)
- A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery (PHASE4)
- Effect of Intracameral Dexamethasone After Phacoemulsification in Diabetics on Corneal Endothelial Cell Density (PHASE4)
- Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexycu intracameral dexamethasone CI brief — competitive landscape report
- Dexycu intracameral dexamethasone updates RSS · CI watch RSS
- Research Insight LLC portfolio CI